Despite advances in understanding the clinical and biological aspects of myeloid leukemia in children with Down syndrome (DS), little is known about the mechanisms of relapse. Upon relapse, patients face a poor outcome, and there is no consensus on treatment. Future studies need to be focused on this challenging aspect of leukemia in children with DS.
[Leukemia]
7992332
BBBBBBBB
items
1
apa
0
default
asc
1
166730
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/